These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 24709544)

  • 1. Proteases as activators for cytotoxic prodrugs in antitumor therapy.
    Weidle UH; Tiefenthaler G; Georges G
    Cancer Genomics Proteomics; 2014; 11(2):67-79. PubMed ID: 24709544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of a tumor protease-activated pore-forming toxin.
    Potrich C; Tomazzolli R; Dalla Serra M; Anderluh G; Malovrh P; Macek P; Menestrina G; Tejuca M
    Bioconjug Chem; 2005; 16(2):369-76. PubMed ID: 15769091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.
    Wallace PM; Senter PD
    Methods Find Exp Clin Pharmacol; 1994 Sep; 16(7):505-12. PubMed ID: 7885077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the membrane-anchored serine protease testisin with a novel engineered anthrax toxin prodrug to kill tumor cells and reduce tumor burden.
    Martin EW; Buzza MS; Driesbaugh KH; Liu S; Fortenberry YM; Leppla SH; Antalis TM
    Oncotarget; 2015 Oct; 6(32):33534-53. PubMed ID: 26392335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
    Lu JY; Lowe DA; Kennedy MD; Low PS
    J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
    Janssen S; Jakobsen CM; Rosen DM; Ricklis RM; Reineke U; Christensen SB; Lilja H; Denmeade SR
    Mol Cancer Ther; 2004 Nov; 3(11):1439-50. PubMed ID: 15542783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of CD95L fusion protein prodrugs by tumor-associated proteases.
    Watermann I; Gerspach J; Lehne M; Seufert J; Schneider B; Pfizenmaier K; Wajant H
    Cell Death Differ; 2007 Apr; 14(4):765-74. PubMed ID: 17053806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The serine proteases and their function in neuronal death processes].
    Fuster Lluch O; Galindo MF; Ceña V; Jordán J
    Rev Neurol; 2004 Mar 1-15; 38(5):449-57. PubMed ID: 15029525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index.
    Desnoyers LR; Vasiljeva O; Richardson JH; Yang A; Menendez EE; Liang TW; Wong C; Bessette PH; Kamath K; Moore SJ; Sagert JG; Hostetter DR; Han F; Gee J; Flandez J; Markham K; Nguyen M; Krimm M; Wong KR; Liu S; Daugherty PS; West JW; Lowman HB
    Sci Transl Med; 2013 Oct; 5(207):207ra144. PubMed ID: 24132639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enzyme-catalyzed activation of anticancer prodrugs.
    Rooseboom M; Commandeur JN; Vermeulen NP
    Pharmacol Rev; 2004 Mar; 56(1):53-102. PubMed ID: 15001663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
    Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
    Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrug applications for targeted cancer therapy.
    Giang I; Boland EL; Poon GM
    AAPS J; 2014 Sep; 16(5):899-913. PubMed ID: 25004822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative toxicity and efficacy of engineered anthrax lethal toxin variants with broad anti-tumor activities.
    Peters DE; Hoover B; Cloud LG; Liu S; Molinolo AA; Leppla SH; Bugge TH
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):220-9. PubMed ID: 24971906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of prodrugs for enzyme-mediated, tumor-selective therapy.
    Yoon KJ; Potter PM; Danks MK
    Curr Med Chem Anticancer Agents; 2005 Mar; 5(2):107-13. PubMed ID: 15777218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
    Warnecke A; Fichtner I; Sass G; Kratz F
    Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.